article thumbnail

Atrial Fibrillation’s Downstream Consequences

CardiacWire

A BMJ study out of Denmark provided alarming new insights into atrial fibrillation’s impact on patients’ future cardiovascular health, while highlighting the need to improve post-AFib heart failure and stroke prevention. The researchers analyzed 2000-2022 data from 3.5M in 2011-2022. overall, increasing from 24.2%

AFIB 105
article thumbnail

Novartis Reclaims Anthos, Reenters Factor XI Race

CardiacWire

Anthos subsequently kicked off three phase 3 trials in 2022, and wrapping up these studies by 2026 will now be Novartis responsibility. Anthos LILAC trial is focused on preventing stroke and systemic embolism in AFib patients, while ASTER and MAGNOLIA aim to use abelacimab to address VTE and GI cancer.

AFIB 102
article thumbnail

Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC

DAIC

Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.

AFIB 52
article thumbnail

CTA and ACC Collaborate to Tackle Cardiovascular Disease with Technology

DAIC

This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022. The framework outlines opportunities for the broader integration of the technology into the workflow for screening and diagnosing cardiovascular disease, using AFib and Hypertension as examples.

article thumbnail

Back to basics: what's going on here?

Dr. Smith's ECG Blog

We've periodically reviewed cases regarding Pacemaker Troubleshooting ( See the February 18, 2024 post — the January 13, 2024 post — the October 19, 2022 post — the August 3, 2022 post — the May 21, 2023 post — the June 19, 2024 post — and the November 9, 2018 post , to name a number of them ).

Pacemaker 110
article thumbnail

GE HealthCare Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation

DAIC

1] Within the complex umbrella of cardiology care and cardiovascular disease, atrial fibrillation ( AFib ) is the most common arrhythmia diagnosed in clinical practice with projections indicating that the prevalence of AFib could reach 15.9 2022 May, 79 (19) 1932–1948. million people in the United States by 2050 and 17.9

article thumbnail

What is this ECG finding? Do you understand it before you hear the clinical context?

Dr. Smith's ECG Blog

The rhythm is irregularly irregular, and appears to be AFib with a fairly slow ventricular response ( overall rate <70/minute ) — although marked baseline artifact renders the search for atrial activity futile. Baseline artifact is no longer present.

Blog 137